279 related articles for article (PubMed ID: 15867345)
1. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
Vidal M; Wells S; Ryan A; Cagan R
Cancer Res; 2005 May; 65(9):3538-41. PubMed ID: 15867345
[TBL] [Abstract][Full Text] [Related]
2. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Carlomagno F; Vitagliano D; Guida T; Ciardiello F; Tortora G; Vecchio G; Ryan AJ; Fontanini G; Fusco A; Santoro M
Cancer Res; 2002 Dec; 62(24):7284-90. PubMed ID: 12499271
[TBL] [Abstract][Full Text] [Related]
3. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
4. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
[TBL] [Abstract][Full Text] [Related]
5. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
6. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
Hofstra RM; van der Luijt RB; Lips CJ
Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic activation of the ret protooncogene in thyroid cancer.
Takahashi M
Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
[TBL] [Abstract][Full Text] [Related]
8. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
9. Drosophila as a novel therapeutic discovery tool for thyroid cancer.
Das T; Cagan R
Thyroid; 2010 Jul; 20(7):689-95. PubMed ID: 20578898
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
11. Different mutations of the RET gene cause different human tumoral diseases.
Santoro M; Melillo RM; Carlomagno F; Visconti R; De Vita G; Salvatore G; Fusco A; Vecchio G
Biochimie; 1999 Apr; 81(4):397-402. PubMed ID: 10401675
[TBL] [Abstract][Full Text] [Related]
12. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of RET activation in human cancer.
Santoro M; Melillo RM; Carlomagno F; Fusco A; Vecchio G
Ann N Y Acad Sci; 2002 Jun; 963():116-21. PubMed ID: 12095936
[TBL] [Abstract][Full Text] [Related]
15. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
16. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
18. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
Fink M; Weinhüsel A; Niederle B; Haas OA
Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
[TBL] [Abstract][Full Text] [Related]
19. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
Lodish MB; Stratakis CA
Expert Rev Anticancer Ther; 2008 Apr; 8(4):625-32. PubMed ID: 18402529
[TBL] [Abstract][Full Text] [Related]
20. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.
Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP
Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
